The 2024 Gold Rush: Unleashing Market Potential

Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.

Get your free information kit NOW, before it's too late.

CRNX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.00%

Insider Buying (Last 12 Months): $110,300.00

Insider Selling (Last 12 Months): $19,243,683.05

Crinetics Pharmaceuticals Insider Trading History Chart

Crinetics Pharmaceuticals Share Price & Price History

^$49.68

▼ -1.21 (-2.38%)

As of 05/9/2024 03:40 PM ET

Days: 30 | 90 | 365

Did You Get Your Free Bitcoin Yet?

From Crypto Swap Profits | Ad

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

Crinetics Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Dana Pizzuti	Insider	Sell	14,375	$44.47	$639,256.25	27,786
4/4/2024	Richard Scott Struthers	CEO	Sell	40,951	$49.17	$2,013,560.67	237,835
3/28/2024	Stephanie Okey	Director	Sell	17,500	$46.38	$811,650.00	6,000
3/22/2024	Jeff E Knight	COO	Sell	32,359	$44.31	$1,433,827.29	52,580
3/20/2024	Dana Pizzuti	Insider	Sell	15,089	$44.06	$664,821.34	27,786
3/20/2024	Matthew K. Fust	Director	Sell	60,000	$44.14	$2,648,400.00	18,536
3/19/2024	Marc Wilson	CFO	Sell	6,942	$42.91	$297,881.22	110,630
1/25/2024	Stephen F. Betz	Insider	Sell	3,000	$37.26	$111,780.00	73,298
1/10/2024	Stephen F. Betz	Insider	Sell	3,000	$37.65	$112,950.00	76,298
1/3/2024	Dana Pizzuti	Insider	Sell	14,375	$35.00	$503,125.00	5,911
1/2/2024	Marc Wilson	CFO	Sell	10,000	$35.47	$354,700.00	96,055
12/26/2023	Stephen F. Betz	Insider	Sell	3,000	$35.89	$107,670.00	79,298
12/21/2023	Dana Pizzuti	Insider	Sell	9,583	$34.57	$331,284.31	5,911
12/11/2023	Stephen F. Betz	Insider	Sell	3,000	$32.87	$98,610.00	82,298
11/27/2023	Stephen F. Betz	Insider	Sell	3,000	$31.84	$95,520.00	85,298
11/3/2023	Richard Scott Struthers	CEO	Sell	199,082	$30.56	$6,083,945.92	135,522
11/1/2023	Marc Wilson	CFO	Sell	10,000	$28.75	$287,500.00	95,601
10/17/2023	Alan Seth Krasner	Insider	Sell	7,000	$30.00	$210,000.00	43,210
7/13/2023	Richard Scott Struthers	CEO	Sell	14,157	$20.35	$288,094.95	630,805
7/11/2023	Richard Scott Struthers	CEO	Sell	24,384	$20.14	$491,093.76	656,421
6/20/2023	Marc Wilson	CFO	Sell	30,922	$19.97	$617,512.34	95,158
6/16/2023	Richard Scott Struthers	CEO	Sell	50,000	$20.81	$1,040,500.00	680,805
6/8/2023	Coelho Rogerio Vivaldi	Director	Buy	5,000	$22.06	$110,300.00	5,000
4/5/2023	Dana Pizzuti	Insider	Sell	8,212	$16.15	$132,623.80	4,500
1/25/2023	Stephen F. Betz	Insider	Sell	8,336	$21.07	$175,639.52	67,815
1/17/2023	Stephen F. Betz	Insider	Sell	3,126	$18.00	$56,268.00	76,151
12/15/2022	Stephen F. Betz	Insider	Sell	3,126	$16.00	$50,016.00	82,403
12/1/2022	Stephen F. Betz	Insider	Sell	3,126	$17.84	$55,767.84	84,968
11/15/2022	Stephen F. Betz	Insider	Sell	3,126	$18.72	$58,518.72	88,094
10/17/2022	Stephen F. Betz	Insider	Sell	3,126	$17.73	$55,423.98	94,346
10/3/2022	Stephen F. Betz	Insider	Sell	3,126	$19.64	$61,394.64	97,472
9/15/2022	Stephen F. Betz	Insider	Sell	4,168	$21.01	$87,569.68	100,598
9/7/2022	Stephen F. Betz	Insider	Sell	1,042	$21.00	$21,882.00	104,766
7/26/2022	Jeff E Knight	COO	Sell	1,152	$20.70	$23,846.40	4,950
7/13/2022	Matthew K. Fust	Director	Sell	5,700	$20.96	$119,472.00	12,536
5/2/2022	Stephen F. Betz	Insider	Sell	3,247	$20.10	$65,264.70	107,598
4/18/2022	Perceptive Advisors Llc	Major Shareholder	Buy	157,515	$22.22	$3,499,983.30	5,321,032
4/18/2022	Stephen F. Betz	Insider	Sell	5,664	$25.81	$146,187.84	110,845
4/13/2022	Richard Scott Struthers	CEO	Sell	138,643	$26.83	$3,719,791.69	730,805
4/5/2022	Richard Scott Struthers	CEO	Sell	21,357	$25.34	$541,186.38	57,400
4/4/2022	Stephen F. Betz	Insider	Sell	9,000	$23.97	$215,730.00	116,509
3/31/2022	Stephen F. Betz	Insider	Sell	4,164	$21.06	$87,693.84
3/1/2022	Stephen F. Betz	Insider	Sell	3,123	$19.73	$61,616.79
2/7/2022	Ajay Madan	Insider	Sell	13,411	$17.83	$239,118.13
2/1/2022	Stephen F. Betz	Insider	Sell	3,123	$18.79	$58,681.17
1/18/2022	Stephen F. Betz	Insider	Sell	4,168	$23.29	$97,072.72
1/3/2022	Stephen F. Betz	Insider	Sell	7,168	$28.02	$200,847.36
12/28/2021	Stephen F. Betz	Insider	Sell	3,000	$27.95	$83,850.00
12/15/2021	Stephen F. Betz	Insider	Sell	5,668	$24.14	$136,825.52
12/1/2021	Stephen F. Betz	Insider	Sell	5,668	$27.38	$155,189.84
11/8/2021	Stephen F. Betz	Insider	Sell	3,900	$28.42	$110,838.00
11/5/2021	Stephen F. Betz	Insider	Sell	12,600	$27.95	$352,170.00
11/1/2021	Matthew K. Fust	Director	Sell	8,954	$25.50	$228,327.00
11/1/2021	Stephen F. Betz	Insider	Sell	5,668	$24.79	$140,509.72
10/27/2021	Stephen F. Betz	Insider	Sell	3,000	$24.00	$72,000.00
10/25/2021	Perceptive Advisors Llc	Major Shareholder	Buy	1,200,000	$19.80	$23,760,000.00
10/21/2021	Stephen F. Betz	Insider	Sell	1,042	$21.10	$21,986.20
9/8/2021	Matthew K. Fust	Director	Sell	6,046	$25.50	$154,173.00	18,582
9/7/2021	Richard Scott Struthers	CEO	Sell	30,000	$25.00	$750,000.00
7/26/2021	Matthew K. Fust	Director	Sell	5,000	$19.59	$97,950.00
7/19/2021	Matthew K. Fust	Director	Sell	5,000	$19.50	$97,500.00	17,536
7/12/2021	Matthew K. Fust	Director	Sell	5,000	$20.71	$103,550.00

Trump’s “Tax Free” Retirement Strategy

From Gold Safe Exchange | Ad

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

SEC Filings (Institutional Ownership Changes) for Crinetics Pharmaceuticals (NASDAQ:CRNX)

98.51% of Crinetics Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Crinetics Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/9/2024	Lord Abbett & CO. LLC	964,568	$45.15M	0.1%	+24.1%	1.225%
5/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	542,708	$25.40M	0.1%	-17.6%	0.689%
5/8/2024	Entropy Technologies LP	10,878	$0.51M	0.1%	-71.7%	0.014%
5/8/2024	ProShare Advisors LLC	16,731	$0.78M	0.0%	+11.0%	0.021%
5/8/2024	Russell Investments Group Ltd.	51,334	$2.40M	0.0%	+366,571.4%	0.065%
5/7/2024	Sei Investments Co.	29,669	$1.39M	0.0%	+75.9%	0.038%
5/7/2024	Swiss National Bank	126,500	$5.92M	0.0%	+21.4%	0.161%
5/7/2024	Lisanti Capital Growth LLC	69,225	$3.24M	0.8%	-30.9%	0.088%
5/7/2024	Oppenheimer Asset Management Inc.	4,276	$0.20M	0.0%	N/A	0.005%
5/7/2024	Oppenheimer & Co. Inc.	4,674	$0.22M	0.0%	N/A	0.006%
5/7/2024	SG Americas Securities LLC	5,967	$0.28M	0.0%	N/A	0.008%
5/2/2024	Jennison Associates LLC	2,817,854	$131.90M	0.1%	+10.6%	3.579%
5/1/2024	BNP Paribas Financial Markets	45,960	$2.15M	0.0%	-74.5%	0.058%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	32,525	$1.52M	0.0%	-17.1%	0.041%
4/29/2024	Principal Financial Group Inc.	14,976	$0.70M	0.0%	-5.7%	0.022%
4/29/2024	China Universal Asset Management Co. Ltd.	13,364	$0.63M	0.1%	+73.1%	0.017%
4/29/2024	HighMark Wealth Management LLC	17,215	$0.81M	0.5%	+305.1%	0.022%
4/17/2024	Hennion & Walsh Asset Management Inc.	38,087	$1.78M	0.1%	+2.5%	0.055%
3/11/2024	Vanguard Group Inc.	3,502,452	$124.62M	0.0%	+2.8%	5.032%
3/5/2024	Fisher Asset Management LLC	441,295	$15.70M	0.0%	+719.3%	0.634%
3/5/2024	Wellington Management Group LLP	3,245,105	$115.46M	0.0%	-10.9%	4.663%
3/1/2024	Goldman Sachs Group Inc.	650,173	$23.13M	0.0%	+17.7%	0.973%
2/26/2024	Teachers Retirement System of The State of Kentucky	40,603	$1.45M	0.0%	+15.3%	0.061%
2/26/2024	Perceptive Advisors LLC	1,255,512	$44.67M	1.0%	-0.7%	1.880%
2/20/2024	Eventide Asset Management LLC	1,059,633	$37.70M	0.6%	+4.0%	1.586%
2/20/2024	Quarry LP	1,000	$36K	0.0%	N/A	0.001%
2/15/2024	Opaleye Management Inc.	307,500	$10.94M	2.9%	-16.9%	0.460%
2/15/2024	Parkman Healthcare Partners LLC	120,652	$4.29M	0.6%	+20.7%	0.181%
2/15/2024	Frazier Life Sciences Management L.P.	397,483	$14.14M	0.8%	-75.0%	0.595%
2/14/2024	First Light Asset Management LLC	1,987,772	$70.73M	5.7%	+25.5%	2.976%
2/14/2024	Point72 Asset Management L.P.	3,416,900	$121.57M	0.3%	-19.1%	5.115%
2/14/2024	Avidity Partners Management LP	529,000	$18.82M	0.7%	-13.3%	0.792%
2/14/2024	Seven Eight Capital LP	34,912	$1.24M	0.1%	N/A	0.052%
2/14/2024	Vestal Point Capital LP	450,000	$16.01M	1.7%	N/A	0.674%
2/13/2024	Rafferty Asset Management LLC	244,289	$8.69M	0.0%	+23.5%	0.366%
2/13/2024	NEOS Investment Management LLC	13,481	$0.48M	0.0%	N/A	0.020%
2/12/2024	TD Asset Management Inc	176,426	$6.28M	0.0%	+26.5%	0.264%
2/9/2024	Franklin Resources Inc.	413,209	$14.70M	0.0%	+197.6%	0.619%
2/9/2024	GW&K Investment Management LLC	479,063	$17.05M	0.2%	-0.8%	0.717%
2/9/2024	Trexquant Investment LP	22,644	$0.81M	0.0%	+205.5%	0.034%
2/7/2024	Principal Financial Group Inc.	15,885	$0.57M	0.0%	-8.2%	0.024%
2/7/2024	Dimensional Fund Advisors LP	659,921	$23.48M	0.0%	-11.4%	0.988%
2/7/2024	Jump Financial LLC	27,083	$0.96M	0.0%	-43.0%	0.041%
2/7/2024	BNP Paribas Financial Markets	180,495	$6.42M	0.0%	-40.7%	0.270%
2/7/2024	Teacher Retirement System of Texas	12,198	$0.43M	0.0%	-12.0%	0.018%
2/7/2024	E Fund Management Co. Ltd.	13,069	$0.47M	0.0%	+28.7%	0.020%
2/6/2024	Charles Schwab Investment Management Inc.	470,373	$16.74M	0.0%	+2.0%	0.704%
2/6/2024	Lisanti Capital Growth LLC	100,245	$3.57M	0.8%	+100.6%	0.150%
2/6/2024	AJOVista LLC	1,630	$58K	0.1%	N/A	0.002%
2/6/2024	Swiss National Bank	104,200	$3.71M	0.0%	-10.5%	0.156%
2/6/2024	Fisher Asset Management LLC	440,893	$15.69M	0.0%	+718.6%	0.660%
2/5/2024	Victory Capital Management Inc.	184,107	$6.55M	0.0%	+309.2%	0.276%
2/1/2024	RWA Wealth Partners LLC	5,696	$0.20M	0.0%	N/A	0.009%
2/1/2024	Jennison Associates LLC	2,547,683	$90.65M	0.1%	+77.7%	3.814%
2/1/2024	Handelsbanken Fonder AB	12,500	$0.45M	0.0%	N/A	0.019%
1/31/2024	abrdn plc	101,196	$3.60M	0.0%	N/A	0.151%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	8,674	$0.31M	0.0%	-14.9%	0.013%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	39,218	$1.40M	0.0%	+6.4%	0.059%
1/24/2024	Arizona State Retirement System	14,789	$0.53M	0.0%	-1.9%	0.022%
1/24/2024	China Universal Asset Management Co. Ltd.	7,721	$0.28M	0.1%	+450.3%	0.012%
1/23/2024	HighMark Wealth Management LLC	4,250	$0.15M	0.1%	N/A	0.006%
1/16/2024	Legato Capital Management LLC	11,575	$0.41M	0.1%	N/A	0.017%
12/18/2023	Vanguard Group Inc.	3,407,035	$101.33M	0.0%	+24.7%	5.100%
12/7/2023	Hudson Bay Capital Management LP	7,500	$0.22M	0.0%	N/A	0.011%
12/1/2023	Wellington Management Group LLP	3,640,235	$108.26M	0.0%	+1.1%	5.449%
11/15/2023	Laurion Capital Management LP	346,637	$10.31M	0.1%	N/A	0.519%
11/15/2023	Acuta Capital Partners LLC	94,000	$2.80M	1.9%	N/A	0.141%
11/15/2023	Alps Advisors Inc.	40,328	$1.20M	0.0%	+1.6%	0.060%
11/15/2023	Affinity Asset Advisors LLC	450,000	$13.38M	3.8%	N/A	0.674%
11/15/2023	Glenmede Trust Co. NA	7,518	$0.22M	0.0%	N/A	0.011%
11/14/2023	Eventide Asset Management LLC	1,018,782	$30.30M	0.5%	+134.3%	1.525%
11/14/2023	AWM Investment Company Inc.	15,000	$0.45M	0.1%	N/A	0.022%
11/14/2023	Schonfeld Strategic Advisors LLC	277,208	$8.24M	0.1%	N/A	0.415%
11/14/2023	MBB Public Markets I LLC	8,702	$0.26M	0.0%	-32.0%	0.013%
11/14/2023	Avidity Partners Management LP	610,000	$18.14M	0.7%	N/A	0.913%
11/14/2023	Monashee Investment Management LLC	27,371	$0.81M	0.3%	N/A	0.041%
11/14/2023	Profund Advisors LLC	33,826	$1.01M	0.1%	+32.2%	0.051%
11/13/2023	Natixis Advisors L.P.	25,630	$0.76M	0.0%	+25.7%	0.038%
11/13/2023	EAM Investors LLC	94,189	$2.80M	0.5%	N/A	0.141%
11/13/2023	Silverarc Capital Management LLC	220,000	$6.54M	2.0%	N/A	0.329%
11/13/2023	FMR LLC	2,140,861	$63.67M	0.0%	+97.7%	3.205%
11/13/2023	Rafferty Asset Management LLC	197,741	$5.88M	0.0%	+43.1%	0.296%
11/13/2023	Kestra Advisory Services LLC	7,431	$0.22M	0.0%	N/A	0.011%
11/13/2023	E Fund Management Co. Ltd.	10,155	$0.30M	0.0%	N/A	0.015%
11/9/2023	Rhumbline Advisers	106,554	$3.17M	0.0%	+18.2%	0.195%
11/9/2023	Deutsche Bank AG	30,210	$0.90M	0.0%	+30.9%	0.055%
11/9/2023	Citigroup Inc.	83,772	$2.49M	0.0%	+51.3%	0.153%
11/9/2023	UBS Group AG	81,858	$2.43M	0.0%	-43.8%	0.150%
11/8/2023	Campbell & CO Investment Adviser LLC	63,917	$1.90M	0.2%	+196.0%	0.117%
11/8/2023	Vivo Capital LLC	350,000	$10.41M	1.3%	N/A	0.640%
11/8/2023	Charles Schwab Investment Management Inc.	461,303	$13.72M	0.0%	+31.5%	0.843%
11/8/2023	Swiss National Bank	116,400	$3.46M	0.0%	+41.6%	0.213%
11/8/2023	Amalgamated Bank	6,298	$0.19M	0.0%	+10.4%	0.012%
11/8/2023	Moody Aldrich Partners LLC	61,979	$1.84M	0.3%	N/A	0.113%
11/7/2023	Virtus ETF Advisers LLC	4,849	$0.14M	0.1%	-9.1%	0.009%
11/7/2023	New York State Common Retirement Fund	27,681	$0.82M	0.0%	+21.7%	0.051%
11/7/2023	Barclays PLC	113,282	$3.37M	0.0%	+23.0%	0.207%
11/7/2023	Jump Financial LLC	47,476	$1.41M	0.1%	N/A	0.087%
11/7/2023	Arizona State Retirement System	15,070	$0.45M	0.0%	+42.2%	0.028%
11/6/2023	Victory Capital Management Inc.	44,990	$1.34M	0.0%	N/A	0.082%

Data available starting January 2016

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $49.68

$49.61

$51.00

50 Day Range

MA: $44.29

$37.93

$50.89

52 Week Range

Now: $49.68

$15.76

$51.29

Volume

411,734 shs

Average Volume

770,324 shs

Market Capitalization

$3.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Who are the company insiders with the largest holdings of Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals' top insider investors include:
Richard Scott Struthers (CEO)
Marc Wilson (CFO)
Stephen F Betz (Insider)
Jeff E Knight (COO)
Alan Seth Krasner (Insider)
Dana Pizzuti (Insider)
Matthew K Fust (Director)
Stephanie Okey (Director)
Coelho Rogerio Vivaldi (Director)
Learn More about top insider investors at Crinetics Pharmaceuticals.
Who are the major institutional investors of Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals' top institutional investors include:
Jennison Associates LLC — 3.58%
Lord Abbett & CO. LLC — 1.23%
BNP PARIBAS ASSET MANAGEMENT Holding S.A. — 0.69%
Swiss National Bank — 0.16%
Lisanti Capital Growth LLC — 0.09%
Russell Investments Group Ltd. — 0.07%
Learn More about top institutional investors of Crinetics Pharmaceuticals stock.
Which institutional investors are selling Crinetics Pharmaceuticals stock?: During the previous quarter, CRNX stock was sold by these institutional investors:
BNP Paribas Financial Markets
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
Lisanti Capital Growth LLC
Entropy Technologies LP
Mirae Asset Global Investments Co. Ltd.
Principal Financial Group Inc.
During the last year, company insiders that have sold Crinetics Pharmaceuticals company stock include:
Richard Scott Struthers (CEO)
Marc Wilson (CFO)
Stephen F Betz (Insider)
Jeff E Knight (COO)
Alan Seth Krasner (Insider)
Dana Pizzuti (Insider)
Matthew K Fust (Director)
Stephanie Okey (Director)
Learn More investors selling Crinetics Pharmaceuticals stock.
Which institutional investors are buying Crinetics Pharmaceuticals stock?: In the last quarter, CRNX stock was bought by institutional investors including:
Jennison Associates LLC
Lord Abbett & CO. LLC
Russell Investments Group Ltd.
Swiss National Bank
HighMark Wealth Management LLC
Sei Investments Co.
SG Americas Securities LLC
China Universal Asset Management Co. Ltd.